Literature DB >> 18676118

Development and preliminary validation of the NePIQoL: a quality-of-life measure for neuropathic pain.

Helen M Poole1, Peter Murphy, Turo J Nurmikko.   

Abstract

Neuropathic pain is frequently associated with negative effects on quality of life (QoL), affecting physical, social, and psychological functioning. Of many existing scales used to measure QoL, none have been validated in a neuropathic pain patient population. This study reports on the development and preliminary psychometric evaluation of the Neuropathic Pain Impact on Quality-of-Life questionnaire (NePIQoL), a measure to assess QoL in neuropathic pain. In Phase I, focus groups with 27 patients and a panel of experts identified QoL issues for inclusion in the measure. Initial items (152) and response categories were pretested using cognitive interviewing (18 patients). Following this, the number of items was reduced to 91. In Phase II, the 91-item version of the NePIQoL was administered to a further 112 patients, poorly performing items were identified, and internal consistency was examined. In Phase III, the revised NePIQoL was administered to a further 110 patients on two occasions to examine validity and test-retest reliability. Qualitative and quantitative pretesting led to extensive revision, resulting in a final measure of 42 items. Finally, Phase IV tested the concurrent validity and responsiveness of the NePIQoL. The authors conclude that the NePIQoL is an acceptable, patient-derived, neuropathic pain-specific measure with evidence of reliability, validity, and temporal stability.

Entities:  

Mesh:

Year:  2008        PMID: 18676118     DOI: 10.1016/j.jpainsymman.2008.01.012

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  4 in total

1.  Towards a better quality of life (QoL) for patients with pituitary diseases: results from a focus group study exploring QoL.

Authors:  Cornelie D Andela; Nicolasine D Niemeijer; Margreet Scharloo; Jitske Tiemensma; Shaaji Kanagasabapathy; Alberto M Pereira; Noëlle G A Kamminga; Ad A Kaptein; Nienke R Biermasz
Journal:  Pituitary       Date:  2015-02       Impact factor: 4.107

2.  Using cognitive pretesting in scale development for Parkinson's disease: the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) example.

Authors:  Barbara C Tilley; Nancy R LaPelle; Christopher G Goetz; Glenn T Stebbins
Journal:  J Parkinsons Dis       Date:  2014       Impact factor: 5.568

3.  Estimating the burden of disease in chronic pain with and without neuropathic characteristics: does the choice between the EQ-5D and SF-6D matter?

Authors:  Nicola Torrance; Kenny D Lawson; Ebenezer Afolabi; Michael I Bennett; Michael G Serpell; Kate M Dunn; Blair H Smith
Journal:  Pain       Date:  2014-07-11       Impact factor: 6.961

4.  The analgesic effect of therapeutic rTMS is not mediated or predicted by comorbid psychiatric or sleep disorders.

Authors:  Pauliina Lindholm; Salla Lamusuo; Tero Taiminen; Arja Virtanen; Antti Pertovaara; Heli Forssell; Nora Hagelberg; Satu Jääskeläinen
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.